Mezzion Pharma

At a glance

Mezzion Pharma filed 35 disclosures in the last 12 months, including 11 insider, 4 5% holder and 1 issuance. The most recent key filing was on Oct 29: CEO bought 1,940 sh on the market at an average ₩51,537, Oct 29.

The 2025 annual report lists 18 employees with an average tenure of 7 years and average pay of ₩63.7M. Its 8 directors and auditors were paid ₩94M each on average. It paid no cash dividend for 2025. 박동현 and related parties held 27.29% at year end.

Of 1 recent 5%+ holder report, 0 raised and 1 cut a stake; the largest stake reported was 6.52% on Oct 8.

From the 2025 annual report

Staff: 18 (14 men, 4 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩1.1B. Directors and auditors: 8, paid ₩756M in total.

No cash dividend was paid for 2025.

Largest shareholder

박동현 holds 6.09%; with 9 related parties the group holds 27.29% of common shares at year end (from 28.01% at the start of the year).

Auditor: 한울회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports